Application of nanomaterials for the treatment of glioblastoma
DOI:
https://doi.org/10.62051/msbcrx04Keywords:
Glioblastoma; Nanomaterials; Blood-brain barrier; Drug delivery.Abstract
Glioblastoma, as the most severe type of primary brain tumor, presents great difficulties in treatment due to its fast-growing nature, recurrence, and resistance to typical treatment methods. A particularly hard challenge is the blood-brain barrier (BBB), which makes it difficult for many drugs to reach tumor regions in enough amounts for the treatment to work well. Nanomaterials may provide one possibility for enhancing immunotherapy in glioblastoma by improving the delivery of drugs, helping them cross the BBB, and adjusting immune responses. This research looks at recent progress in using nanomaterials for glioblastoma treatment, focusing on types of organic and inorganic nanoparticles. Organic nanomaterials like lipid-based or polymer nanoparticles have the potential to deliver drugs directly to the tumor, with longer-lasting effects. Inorganic nanomaterials, such as magnetic nanoparticles, iron oxide ones, or gold nanoparticles, have been shown to be helpful for hyperthermia and photothermal therapy, as well as improving radiotherapy. These nanomaterials can be used alone or as vaccine adjuvants, providing practical options for getting through the BBB and delivering therapeutic agents to the tumor site. The integration of nanomaterials into glioblastoma treatments holds a certain potential to create better treatment plans for glioblastoma cases.
Downloads
References
[1] A. Squalli Houssaini, S. Lamrabet, J. P. Nshizirungu, et al. Glioblastoma vaccines as promising immune-therapeutics: challenges and current status, Vaccines 12(6) (2024) 655.
[2] O. Afzal, A. S. A. Altamimi, M. S. Nadeem, et al. Nanoparticles in drug delivery: From history to therapeutic applications, Nanomaterials, 12(24) (2022) 4494.
[3] F. Hameedat, B. B. Mendes, J. Conniot, et al. Engineering nanomaterials for glioblastoma nanovaccination, Nature Reviews Materials 9 (2024) 628-642.
[4] D. Mendanha, J. V. De Castro, M. R. Casanova, et al. Macrophage cell membrane infused biomimetic liposomes for glioblastoma targeted therapy, Nanomedicine: Nanotechnology, Biology and Medicine 49 (2023) 102663.
[5] D. Mendanha, S. Gimondi, B. M. Costa, et al. Microfluidic-derived docosahexaenoic acid liposomes for glioblastoma therapy, Nanomedicine: Nanotechnology, Biology and Medicine 53 (2023) 102704.
[6] A. Mellinger, L. J. Lubitz, C. Gazaille, et al. The use of liposomes functionalized with the NFL-TBS. 40–63 peptide as a targeting agent to cross the in vitro blood–brain barrier and target glioblastoma cells, International Journal of Pharmaceutics 646 (2023) 123421.
[7] T. Zwain, J. E. Alder, S. Zwayen, et al. Overcoming biological barriers BBB/BBTB by designing PUFA functionalised lipid-based nanocarriers for glioblastoma targeted therapy, Biomaterials Advances 155 (2023) 213660.
[8] S. Mittal, S. Shah, H. N. Yadav, et al. Quality by design engineered, enhanced anticancer activity of temozolomide and resveratrol coloaded NLC and brain targeting via lactoferrin conjugation in treatment of glioblastoma, European Journal of Pharmaceutics and Biopharmaceutics 191 (2023) 175-188.
[9] M. Wiranowska, Advances in the Use of Chitosan and Chlorotoxin-Functionalized Chitosan Polymers in Drug Delivery and Detection of Glioma-A Review, Carbohydrate Polymer Technologies and Applications 7 (2024) 100427.
[10] B. Gabold, F. Adams, S. Brameyer, et al. Transferrin-modified chitosan nanoparticles for targeted nose-to-brain delivery of proteins, Drug Delivery and Translational Research 13(3) (2023) 822-838.
[11] B. Abadi, P. Khazaeli, H. Forootanfar, et al. Chitosan-sialic acid nanoparticles of selenium: Statistical optimization of production, characterization, and assessment of cytotoxic effects against two human glioblastoma cell line, International Journal of Pharmaceutics 637 (2023) 122884.
[12] D. Horvath, M. Basler, PLGA particles in immunotherapy, Pharmaceutics 15(2) (2023) 615.
[13] J. Kuźmińska, A. Sobczak, A. Majchrzak-Celińska, et al. Etoricoxib-Cannabidiol Combo: Potential Role in Glioblastoma Treatment and Development of PLGA-Based Nanoparticles, Pharmaceutics 15(8) (2023) 2104.
[14] M. Younis, S. Shaikh, K. A. Shahzad, et al. Amrubicin encapsulated PLGA NPs inhibits the PI3K/AKT signaling pathway by activating PTEN and inducing apoptosis in TMZ-resistant Glioma, Biomedical Materials 19(2) (2024) 025003.
[15] Y. M. Mofrad, S. Asiaei, H. Shaygani, et al. Investigating the effect of magnetic field and nanoparticles characteristics in the treatment of glioblastoma by magnetic hyperthermia method: an in silico study, Results in Engineering 23 (2024) 102473.
[16] J. Liu, M. Sun, Z. Li, et al. Catalytic nanoreactors promote GLUT1-mediated BBB permeation by generating nitric oxide for potentiating glioblastoma ferroptosis, Chemical Engineering Journal 483 (2024) 149233.
[17] H. Yao, J. Y. Zhou, Chlorin e6-modified iron oxide nanoparticles for photothermal-photodynamic ablation of glioblastoma cells, Frontiers in Bioengineering and Biotechnology 11 (2023) 1248283.
[18] J. Chen, R. Yang, H. Yu, et al. Ultrasmall iron oxide nanoparticles with MRgFUS for enhanced magnetic resonance imaging of orthotopic glioblastoma, Journal of Materials Chemistry B 12(20) (2024) 4833-4842.
[19] B. Zhang, R. Yang, H. Yu, et al. Macrophage membrane-camouflaged nanoclusters of ultrasmall iron oxide nanoparticles for precision glioma theranostics, Biomaterials Science 12(10) (2024) 2705-2716.
[20] S. Qureshi, S. Anjum, M. Hussain, et al. A recent insight of applications of gold nanoparticles in glioblastoma multiforme therapy, International Journal of Pharmaceutics 660 (2024) 124301.
[21] O. Yücel, Y. Aksüt, A. Şengelen, et al. Folate receptor-targeted indomethacin-loaded gold nanoparticles enhance drug chemotherapeutic efficacy in glioblastoma cells and spheroids, Journal of Drug Delivery Science and Technology 100 (2024) 106025.
[22] K. Kostka, V. Sokolova, A. El-Taibany, et al. The Application of Ultrasmall Gold Nanoparticles (2 nm) Functionalized with Doxorubicin in Three-Dimensional Normal and Glioblastoma Organoid Models of the Blood–Brain Barrier, Molecules 29(11) (2024) 2469.
[23] C. He, H. Ding, L. Li, et al. Gold nanoparticles enhance the ability of radiotherapy to induce immunogenic cell death in glioblastoma, International Journal of Nanomedicine 18 (2023) 5701-5712.
[24] J. P. Li, Y. C. Kuo, W. N. Liao, et al. Harnessing nuclear energy to gold nanoparticles for the concurrent chemoradiotherapy of glioblastoma, Nanomaterials 13(21) (2023) 2821.
[25] M. Durand, A. Chateau, J. Jubréaux, et al. Radiosensitization with gadolinium chelate-coated gold nanoparticles prevents aggressiveness and invasiveness in glioblastoma, International Journal of Nanomedicine 18 (2023) 243-261.
Downloads
Published
Conference Proceedings Volume
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
